Table 1 Baseline demographics and characteristics
Characteristic | bTMB ≥10 (ITT) | bTMB ≥16 | ||
|---|---|---|---|---|
Atezolizumab N = 234 | Chemotherapy N = 237 | Atezolizumab n = 145 | Chemotherapy n = 146 | |
Age, median (min–max), years | 66 (39–89) | 66 (33–86) | 65 (39–89) | 66 (40–86) |
Age <65 years, n (%) | 108 (46) | 102 (43) | 72 (50) | 65 (45) |
Male, n (%) | 170 (73) | 176 (74) | 106 (73) | 108 (74) |
Race, n (%) | ||||
White | 167 (71) | 173 (73) | 103 (71) | 106 (73) |
Asian | 38 (16) | 43 (18) | 20 (14) | 32 (22) |
Black | 4 (2) | 2 (<1) | 4 (3) | 1 (<1) |
American Indian/Alaska Native | 3 (1) | 5 (2) | 3 (2) | 2 (1) |
Native Hawaiian/Pacific Islander | 1 (<1) | 0 | 1 (<1) | 0 |
Unknown | 21 (9) | 14 (6) | 14 (10) | 5 (3) |
Baseline ECOG PS per eCRF, n (%) | ||||
0 | 66 (28) | 65 (27) | 40 (28) | 41 (28) |
1 | 166 (71) | 171 (72) | 104 (72) | 105 (72) |
3a | 1 (<1) | 0 | 0 | 0 |
Unknown | 1 (<1) | 1 (<1) | 1 (<1) | 0 |
Tissue available (eCRF), n (%) | 173 (74) | 186 (78) | 106 (73) | 115 (79) |
Tobacco history, n (%) | ||||
Never | 4 (2) | 4 (2) | 4 (3) | 2 (1) |
Current | 81 (35) | 84 (35) | 61 (42) | 53 (36) |
Previous | 149 (64) | 148 (62) | 80 (55) | 91 (62) |
Unknown | 0 | 1 (<1) | ||
Stage at diagnosis, n (%) | ||||
I | 4 (2) | 5 (2) | 3 (2) | 2 (1) |
II | 7 (3) | 9 (4) | 4 (3) | 4 (3) |
III | 34 (15) | 41 (17) | 24 (17) | 23 (16) |
IV | 189 (81) | 182 (77) | 114 (79) | 117 (80) |
Nonsquamous histology per eCRF, n (%) | 168 (72) | 171 (72) | 113 (78) | 112 (77) |
Metastatic sites, median (min–max) | 3 (1–11) | 3 (1–9) | 3 (1–11) | 3 (1–9) |
Sum of longest diameters, median (min–max) | 102 (10–253) | 105 (10–246) | 105 (11–253) | 110 (12–246) |
Liver metastases, n (%) | 50 (21) | 54 (23) | 30 (21) | 26 (18) |
Brain metastases, n (%) | 33 (14) | 46 (19) | 21 (14) | 28 (19) |
